Repurposing empagliflozin in individuals with glycogen storage disease Ib: A value‐based healthcare approach and systematic benefit‐risk assessment
Open Access
- 7 January 2024
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 47 (2) , 244-254
Abstract
Off‐label repurposing of empagliflozin allows pathomechanism‐based treatment of neutropenia/neutrophil‐dysfunction in glycogen storage disease type Ib (GSDIb). From a value‐based healthcare (VBHC) perspective, we here retrospectively studied patient‐reported, clinical and pharmacoeconomic outcomes in 11 GSDIb individuals before and under empagliflozin at two centers (the Netherlands [NL], Austria [AT]), including a budget impact analysis, sensitivity‐analysis, and systematic benefit–risk assessment. Under empagliflozin, all GSDIb individuals reported improved quality‐of‐life‐scores. Neutrophil dysfunction related symptoms allowed either granulocyte colony‐stimulating factor cessation or tapering. Calculated cost savings per patient per year ranged between € 6482–14 190 (NL) and € 1281–41 231 (AT). The budget impact analysis estimated annual total cost savings ranging between € 75 062–225 716 (NL) and € 37 697–231 790 (AT), based on conservative assumptions. The systematic benefit‐risk assessment was favorable. From a VBHC perspective, empagliflozin treatment in GSDIb improved personal and clinical outcomes while saving costs, thereby creating value at multiple pillars. We emphasize the importance to reimburse empagliflozin for GSDIb individuals, further supported by the favorable systematic benefit‐risk assessment. These observations in similar directions in two countries/health care systems strongly suggest that our findings can be extrapolated to other geographical areas and health care systems.Keywords
Funding Information
- Universitair Medisch Centrum Groningen (MD‐PhD 21‐65)
This publication has 22 references indexed in Scilit:
- On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer PatientsFrontiers in Pharmacology, 2020
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2019
- Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiencyProceedings of the National Academy of Sciences, 2019
- Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factorCurrent Opinion in Hematology, 2019
- Update of the Dutch manual for costing studies in health carePLOS ONE, 2017
- Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysisDiabetes, Obesity and Metabolism, 2016
- Drug repositioning and repurposing: terminology and definitions in literatureDrug Discovery Today, 2015
- What Is Value in Health Care?New England Journal of Medicine, 2010
- Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: Results of the European Study on Glycogen Storage Disease Type IThe Journal of Pediatrics, 2000
- Development of a Crohn's Disease Activity IndexGastroenterology, 1976